RESECTABLE MMR-DEFICIENT SOLID TUMORS

Clinical trials for RESECTABLE MMR-DEFICIENT SOLID TUMORS explained in plain language.

Never miss a new study

Get alerted when new RESECTABLE MMR-DEFICIENT SOLID TUMORS trials appear

Sign up with your email to follow new studies for RESECTABLE MMR-DEFICIENT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New Two-Drug combo aims to shrink tumors before surgery

Disease control Recruiting now

This study is testing whether giving two immunotherapy drugs (botensilimab and balstilimab) before surgery can help shrink tumors in patients with various types of solid cancers. The goal is to see if this approach leads to less cancer remaining after surgery and better long-term…

Matched conditions: RESECTABLE MMR-DEFICIENT SOLID TUMORS

Phase: PHASE2, PHASE3 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control

Last updated Mar 27, 2026 12:39 UTC

RESECTABLE MMR-DEFICIENT SOLID TUMORS

Get alerted when new RESECTABLE MMR-DEFICIENT SOLID TUMORS trials appear

New Two-Drug combo aims to shrink tumors before surgery